MX2007004051A - Pi3-quinasas. - Google Patents

Pi3-quinasas.

Info

Publication number
MX2007004051A
MX2007004051A MX2007004051A MX2007004051A MX2007004051A MX 2007004051 A MX2007004051 A MX 2007004051A MX 2007004051 A MX2007004051 A MX 2007004051A MX 2007004051 A MX2007004051 A MX 2007004051A MX 2007004051 A MX2007004051 A MX 2007004051A
Authority
MX
Mexico
Prior art keywords
diseases
inflammatory
allergic
gastro
therapy
Prior art date
Application number
MX2007004051A
Other languages
English (en)
Spanish (es)
Inventor
Eckhart Bauer
Matthias Hoffmann
Matthias Grauert
Trixi Brandl
Steffen Breitfelder
Christoph Hoenke
Frank Buettner
Gerhard Schaenzle
Udo Maier
Alexander Pautsch
Anne T Joergensen
Frank Kalkbrenner
Stefan Peters
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004048877A external-priority patent/DE102004048877A1/de
Priority claimed from DE102005005813A external-priority patent/DE102005005813A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2007004051A publication Critical patent/MX2007004051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2007004051A 2004-10-07 2005-10-05 Pi3-quinasas. MX2007004051A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004048877A DE102004048877A1 (de) 2004-10-07 2004-10-07 PI3-Kinasen
DE102005005813A DE102005005813A1 (de) 2005-02-09 2005-02-09 PI3-Kinasen
PCT/EP2005/055015 WO2006040279A1 (de) 2004-10-07 2005-10-05 Pi3-kinasen

Publications (1)

Publication Number Publication Date
MX2007004051A true MX2007004051A (es) 2007-05-24

Family

ID=35583390

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004051A MX2007004051A (es) 2004-10-07 2005-10-05 Pi3-quinasas.

Country Status (14)

Country Link
US (4) US7691888B2 (enExample)
EP (2) EP1802636B1 (enExample)
JP (1) JP5122287B2 (enExample)
KR (1) KR20070064660A (enExample)
CN (1) CN101048418A (enExample)
AR (1) AR055273A1 (enExample)
AU (1) AU2005293607A1 (enExample)
BR (1) BRPI0516557A (enExample)
CA (1) CA2579279C (enExample)
IL (1) IL182398A0 (enExample)
MX (1) MX2007004051A (enExample)
RU (2) RU2403258C2 (enExample)
TW (1) TW200628475A (enExample)
WO (1) WO2006040279A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
AU2005293607A1 (en) * 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh PI3 kinases
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
MX2008012535A (es) * 2006-04-06 2008-10-10 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles.
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
DE602006002385D1 (de) * 2006-06-26 2008-10-02 Helm Ag Verfahren zur Herstellung von Pramipexole
EP2045253A4 (en) * 2006-06-29 2013-01-23 Nissan Chemical Ind Ltd alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
GB0619611D0 (en) * 2006-10-04 2006-11-15 Ark Therapeutics Ltd Compounds and their use
WO2009039140A1 (en) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
US20110052643A1 (en) * 2008-01-07 2011-03-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
PE20091617A1 (es) * 2008-03-13 2009-11-12 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
WO2009120826A1 (en) * 2008-03-27 2009-10-01 Wyeth 2-aryl- and 2-heteroarylthiazolyl compounds, methods for their preparation and use thereof
RU2506267C2 (ru) 2008-03-31 2014-02-10 Дженентек, Инк. Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение
WO2010007943A1 (ja) * 2008-07-17 2010-01-21 旭化成ファーマ株式会社 含窒素複素環化合物
US20110230472A1 (en) * 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
EP2350084B1 (en) * 2008-10-17 2015-06-24 Boehringer Ingelheim International GmbH Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
GB0900404D0 (en) 2009-01-12 2009-02-11 Addex Pharmaceuticals Sa New compounds 4
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
EP2421872B1 (en) * 2009-04-22 2015-06-10 Boehringer Ingelheim International GmbH Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
US8288379B2 (en) 2009-04-22 2012-10-16 Boehringer Ingelheim International Gmbh Thia-triaza-cyclopentazulenes
ES2432671T3 (es) * 2009-07-02 2013-12-04 Novartis Ag 2-carboxamida cicloamino ureas útiles como inhibidores de PI3K
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
EP2483277B1 (en) * 2009-09-28 2015-12-02 F. Hoffmann-La Roche AG Benzoxepin pi3k inhibitor compounds and methods of use
EP2845592A1 (en) * 2009-09-28 2015-03-11 F. Hoffmann-La Roche AG Benzoxazepin PI3K inhibitor compounds and methods of use
CN102695710B (zh) * 2009-11-13 2015-08-19 默克雪兰诺有限公司 三环吡唑胺衍生物
CN103153062B (zh) 2010-05-24 2015-07-15 因特利凯有限责任公司 杂环化合物及其用途
US20130252944A1 (en) * 2010-07-14 2013-09-26 Christelle Bolea Novel fused pyrazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
GB201011831D0 (en) 2010-07-14 2010-09-01 Addex Pharmaceuticals Sa New compounds 5
TW201245176A (en) 2011-01-26 2012-11-16 Boehringer Ingelheim Int New 5-alkynyl-pyridines
EP2546249A1 (en) 2011-07-15 2013-01-16 Boehringer Ingelheim International Gmbh 5-Alkynyl-pyridines
US8466162B2 (en) 2011-01-26 2013-06-18 Boehringer Ingelheim International Gmbh 5-alkynyl-pyridines
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
RU2013143747A (ru) 2011-03-21 2015-04-27 Ф. Хоффманн-Ля Рош Аг Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения
CA2861496A1 (en) * 2012-02-06 2013-08-15 Glaxosmithkline Intellectual Property (No.2) Limited Pi3k inhibitors for treating cough
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
JP7768505B2 (ja) 2018-06-01 2025-11-12 コーネル・ユニバーシティー Ｐｉ３ｋに関連する疾患または障害に対する併用療法
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
AU2019417833B2 (en) 2018-12-31 2024-11-07 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
EP4387972A1 (en) 2021-08-20 2024-06-26 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5533405A (en) 1978-08-29 1980-03-08 Teijin Ltd Hexahydronaphtho(1',2':4,5)imidazo(2,1-b)thiazole and its preparation
WO1979001080A1 (fr) 1978-05-17 1979-12-13 Teijin Ltd Hexahydronaphtoimidazothiazoles et procede pour leur preparation
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
US5358949A (en) * 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
US5182290A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
TW260664B (enExample) * 1993-02-15 1995-10-21 Otsuka Pharma Factory Inc
JP3670309B2 (ja) 1993-04-01 2005-07-13 第一製薬株式会社 二環性複素環化合物
NO941135L (no) 1993-04-01 1994-10-03 Daiichi Seiyaku Co Tiazolpyrimidin derivater
TW420669B (en) * 1994-03-28 2001-02-01 Nissan Chemical Ind Ltd Pyridine type thiazolidines
AU727654B2 (en) * 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
US7091227B2 (en) * 2000-02-07 2006-08-15 Abbott Gmbh & Co. Kg Benzothiazole derivatives
HUP0300382A3 (en) * 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
US6908932B2 (en) 2001-10-24 2005-06-21 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
MY156407A (en) * 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
EP1349179A1 (en) * 2002-03-18 2003-10-01 ATOFINA Research Conductive polyolefins with good mechanical properties
CA2493843C (en) 2002-07-10 2012-04-17 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
ATE411996T1 (de) 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
JP2006510661A (ja) 2002-12-06 2006-03-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｐｉ３ｋの阻害剤としてのベンズオキサジン−３−オン類及びその誘導体
WO2004056820A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
NO20041733L (no) * 2004-04-28 2005-10-31 Thin Film Electronics Asa Organisk elektronisk krets med funksjonelt mellomsjikt og fremgangsmate til dens fremstilling.
AU2005293607A1 (en) * 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh PI3 kinases
FR2887993B1 (fr) * 2005-07-01 2007-08-03 Commissariat Energie Atomique Dispositif de detection de rayonnements a electrodes empilees et methode de detection de rayonnements ionisants mettant en oeuvre un tel dispositif
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
BRPI0710841A2 (pt) * 2006-04-06 2011-08-23 Boehringer Ingelheim Int compostos derivados de tiazolil dihidroindazóis como inibidores da proteìna quinase, preparações farmacêuticas e o uso das mesmas

Also Published As

Publication number Publication date
RU2403258C2 (ru) 2010-11-10
US20090156554A1 (en) 2009-06-18
AU2005293607A1 (en) 2006-04-20
EP1802636B1 (de) 2013-03-27
US20100113414A1 (en) 2010-05-06
US20060100254A1 (en) 2006-05-11
WO2006040279A1 (de) 2006-04-20
JP2008515852A (ja) 2008-05-15
TW200628475A (en) 2006-08-16
CA2579279C (en) 2013-10-01
US20060106013A1 (en) 2006-05-18
KR20070064660A (ko) 2007-06-21
AR055273A1 (es) 2007-08-15
CN101048418A (zh) 2007-10-03
RU2007116858A (ru) 2008-12-27
CA2579279A1 (en) 2006-04-20
BRPI0516557A (pt) 2008-09-09
IL182398A0 (en) 2007-07-24
JP5122287B2 (ja) 2013-01-16
US8232286B2 (en) 2012-07-31
EP2343303A1 (de) 2011-07-13
EP1802636A1 (de) 2007-07-04
US8207349B2 (en) 2012-06-26
RU2007116861A (ru) 2009-03-20
US7691888B2 (en) 2010-04-06

Similar Documents

Publication Publication Date Title
MX2007004051A (es) Pi3-quinasas.
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2007135026A3 (de) Substituierte pteridine als therapeutika
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
MX2009005279A (es) Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
UA98961C2 (uk) Похідні піразинону та їх застосування у лікуванні легеневих захворювань
MX2010001236A (es) Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
MX2010003774A (es) Formulaciones oftalmicas acuosas.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
MX2007004862A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
WO2004074243A3 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
MX2009004908A (es) Compuestos quimicos.
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
WO2006058867A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal